Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Role of Nucleoside Analogue in Preventing Clinical Reactivation of HBV in HCV/HBV Co-infected Patients Receiving DAA Therapy for Chronic Hepatitis C

NCT04405011 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT04405011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04405011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Role of Nucleoside Analogue in Preventing Clinical Reactivation of HBV in HCV/HBV Co-infected Patients Receiving DAA Therapy for Chronic Hepatitis C
Lead sponsor
National Taiwan University Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 1, 2018
Completion date
December 28, 2020
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hbv/hcv co-infection